Reset

| Population | Percentage | # of Lives |
|---|------------------------|------------------------|
| lan size | | 1,000 |
| dults with obesity (%); BMI ≥ 30 | 42.5% | 425 |
| Adults who are overweight (%); BMI 25.0 - 29.9 | 31.1% | 311 |
| Adults with BMI 27.0-29.0 (%) | 59.8% | 186 |
| Eligible adults with BMI 27.0 - 29.0 & 1+ weight-related comorbidities* (%) | 77.0% | 143 |
| Total adults eligible for AOM use | | 568 |
| AOM utilization rate | 3.0% | 17 |
| Includes diabetes, dyslipidemia, hypertension, obstructiv | e sleep apnea, urinary | incontinence, and asth |


| _ | Market Mix | Market share take | Take from generic | • |
|---|---|--------------------|-------------------|---------------|
| | Brand | WAC per 30 days | Total share | Branded Share |
| | Contrave | \$625.20 | 0.5% | 0.7% |
| | Qsymia (15 - 92mg) | \$199.50 | 0.5% | 0.7% |
| | Saxenda® (liraglutide) injection 3 mg | \$1,349.02 | 10.0% | 13.2% |
| | Wegovy [®] (semaglutide) injection 2.4 mg | \$1,349.02 | 65.0% | 85.5% |
| | Xenical | \$753.71 | 0.0% | 0.0% |
| | Generic use* | \$46.07 | 24.0% | |
| | Branded AOM blended costs | \$1,336.70 | | |
| | Total blended cost | \$1,026.95 | | |
| | | | 13 | |
| | | | 4 | |
| | *Includes diethylpropion, phentermine, benzphetamine, a | nd phendimetrazine | | |

Please see 'Saxenda ISI' tab and 'Wegovy ISI' tab for Important Safety information.

Please <u>click here</u> for Saxenda® Prescribing Information, including Boxed Warning.

Please <u>click here</u> for Wegovy® Prescribing Information, including Boxed Warning.

Anti-Obesity Medication Cost Calculator





| Basic Results | | |
|-----------------------------|--------------|--------------------|
| | Annual Costs | DOT-adjusted Costs |
| Estimated total yearly cost | \$210,064.85 | \$104,326.42 |
| Estimated PMPY cost | \$210.06 | \$104.33 |
| Estimated PMPM cost | \$17.51 | \$8.69 |

| Results including rebate | | |
|---|--------------|--------------------|
| Contrave Rebate | 50.0% | |
| Qsymia (15 - 92mg) Rebate | 25.0% | |
| Saxenda [®] (liraglutide) injection 3 mg Rebate | 40.0% | |
| Wegovy [®] (semaglutide) injection 2.4 mg Rebate | 40.0% | |
| Xenical Rebate | 0.0% | |
| Generic Rebate | 0.0% | |
| | Annual Costs | DOT-adjusted Costs |
| Estimated total yearly cost | \$126,910.25 | \$62,810.91 |
| Estimated PMPY cost | \$126.91 | \$62.81 |
| Estimated PMPM cost | \$10.58 | \$5.23 |
| Results including rebate and employee out of pocket | | |

| | Formulary Tier | | Copay | | insurance |
|--|----------------|-----|--------------|-------|-----------|
| Contrave | Tier 4 | ▼ 0 | \$50.0 | 0 👁 | 0.0% |
| Qsymia (15 - 92mg) | Tier 4 | • | \$50.0 | 0 | 0.0% |
| Saxenda® (liraglutide) injection 3 mg | Tier 4 | ▼ (| \$50.0 | 0 | 0.0% |
| Wegovy® (semaglutide) injection 2.4 mg | Tier 4 | ▼ (| \$50.0 | 0 💿 | 0.0% |
| Xenical | Tier 1 | ▼ (| \$0.0 | 0 💿 | 0.0% |
| Generic | Tier 1 | ▼ 9 | \$10.0 | | 0.0% |
| | | | Annual Costs | DOT-a | djusted C |
| Estimated total yearly cost | | | \$124,271.52 | | 58,818.71 |
| Estimated PMPY cost | | | \$124.27 | T [| \$58.82 |